Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 11
Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Antimicrobials

Overview: Recent Advances in Vaccine Adjuvants

John Rhodes Department of Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, BR3 3BS, UK
Pages 1833-1844 | Published online: 02 Mar 2011

References to Primary Literature

  • Glenny, AT Pope, GC Waddington, H Variation in immunity response to different preparations of diphtheria toxin. Chemistry and Industry 15th June 1926 145.
  • Gupta, RK Relyveld, EH Adverse reactions after injection of adsorbed diphteria-pertussis-tetanus (DPT) vaccines are not only due to pertussis organisms of pertussis components in the vaccine. Vaccine 1991 9 699–702 Comprehensively describes the adverse effects of alum and aluminum salts as adjuvants.
  • Bomford, R Aluminum salts: Perspectives in their use as adjuvants. Immunological Adjuvants and Vaccines. Gregoriadis, G, Allison, AC, Poste, G Plenum Press New York1989 A detailed review of the only adjuvant approved for human use.
  • Dienes, L Schoenheit, EW The reproduction of tuberculin hypersensitiveness in guinea pigs with various protein substances. Amer. Rev. Tuberc. 1929 20 92–96.
  • Freund, J McDermott, K Sensitization to horse serum by means of adjuvants. Proc. Soc. Exp. Biol. Med. 1942 49 548–553.
  • Thibault, P Richou, R Sur l'accroissement de l'immunite antitoxique sous l'inluence de l'addition de diverse substances a l'antigene (anatoxines diphterique et tetanique). C.R. Seances Soc. Biol. 1936 121 718–805.
  • Bomford, R Saponins as immunoadjuvants. Immunological Adjuvants and Vaccines. Gregoriadis, G, Allison, AC, Poste, G Plenum Press New York1989 A detailed review of this adjuvant which may find clinical use in ISCOMS.
  • Chedid, L Audibert, F Lefrancier, P Choay, J Lederer, E Modulation of the immune response by a synthetic adjuvant and analogs. Proc. Natl. Acad. Sci. USA 1976 73 2472–2475.
  • Byars, NE Nakano, G Welch, M Lehman, D Allison, AC Improvement of hepatitis B vaccines by the use of a new adjuvant. Vaccine 1991 9 309–318 Exemplifies the use of this new adjuvant which is nearing approval for human use.
  • Hunter, RL Stricland, F Kedzy, F Studies on the adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophilic-lipophilic balance. J. Immunol. 1981 127 1244–1249.
  • Hunter, RL Bennett, B Howerton, D Buynitsky, S Check, IJ Nonionic block copolymer surfactants as immunological adjuvants: Mechanism of action and novel formulations. Immunological Adjuvants and Vaccines. Gregoriadis, G, Allison, AC, Poste, G Plenum Press New York1989 A comprehensive review of these promising adjuvants.
  • Rietschel, ETh Brade, L Schade, U Seydwl, U Zahringer, U Loppnow, H Flad, H-D Brade, H Bacterial Endotoxins: Relationship between chemical structure and biological activity. Immunological Adjuvants and Vaccines. Gregoriadis, G, Allison, AC, Poste, G Plenum Press New York1989 A thorough review of the structure and properties of the adjuvant component of Gram negative bacteria.
  • Schneerson, R Fattom, A Szu, SC Bryla, D Ulrich, JT Rudbach, JA Schiffman, G Robbins, JB Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response on mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 1991 14 2136–2140.
  • Hui, GSN Tam, LW Chang, SP Case, SE Hashiro, C Siddiqui, WA Shiba, T Kusumo to, S Kotani, S Synthetic low-toxicity mura myl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibiting antibodies to the P. falciparum major merozoite surface protein, gp195. Infect. Immun. 1991 9 266–272.
  • Fitzgerald, TJ Syphilis vaccine: Up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits. Vaccine 1991 9 266–272.
  • Rickman, LS Gordon, DM Wistar, R Krzych, U Gross, M Hollingdale, MR Egan, JE Chulay, JD Hoffman, S Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A and squalane in malaria circumsporozoite protein vaccine. Lancet 1991 337 998–1001 Describes the use in humans of MPA in a candidate malaria vaccine.
  • Allison, AC Gregoriadis, G Liposomes as immunological adjuvants. Nature 1974 252 252–254.
  • Gregoriadis, G Tan, L Xiao, Q The immunoadjuvant action of liposomes: Role of structural characteristics. Immunological Adjuvants and Vaccines. Gregoriadis, G, Allison, AC, Poste, G Plenum Press New York1989 Detailed review of liposomes as adjuvants.
  • Garcon, NMJ Six, HR Universal vaccine carrier: Liposomes that provide T-cell help to weak antigens. J. Immunol 1991 147 2860–2863.
  • Harding, CV Collins, DS Kanagawa, O Unanue, ER Liposome encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol. 1991 147 2860–2863 First report on use of liposomes to differentially target processing pathways.
  • Fries, LF Gordon, DM Richards, RL Egan, JE Hollingdale, MR Gross, M Silverman, C Alving, CR Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 1992 89 358–362 Exemplifies the safe and effective use of a combination adjuvant of liposomes and alum in humans.
  • Morein, B Sundquist, B Hoglund, S Dals Gaard, K Osterhaus, A ISCOM, a novel structure for antigenic presentation of membrane proteins form enveloped viruses. Nature 1984 308 457–459.
  • Morein, B Lovgren, K Hoglund, S Immunostimulatory complex (ISCOM). Immunological Adjuvants and Vaccines. Gregoriadis, G, Allison, AC, Poste, G Plenum Press New York1989 Comprehensive review on ISCOM technology and applications.
  • Jones, PD Tha Hla, R Morein, B Lovgren, K Ada, GL Cellular immune response in the murine lung to local immunisation with influenza A virus glycoproteins in micelles and immunostimulating complexes (ISCOMS). Scand. J. Immunol 1988 27 645–652.
  • Talahashi, H Takeshita, T Morein, B Putney, S Germain, RN Berzofsky, JA Induction of CD8+ cytotoxic T-cells by immunisation with purified HIV-1 envelope protein in ISCOMs. Nature 1990 344 873–875.
  • Mowat, A Donachie, AM Reid, G Jarret, D Immune stimulating complexes containing Quil A and protein antigen prime class I MHC restricted T-lymphocytes in vivo and are immunogenic by the oral route. Immuology 1991 72 317–322 Demonstrates effectiveness of oral administration of ISCOMs in the induction of antibody and CTL responses.
  • Wang, CJ Looney, DJ Li, ML Walfield, AM Ye, J Hosein, B Tam, JP Wong-Staal, F Long term high titer neutralising activity induced by octameric synthetic HIV antigen. Science 1992 256 1560–1563 Demonstrates a new principle in the construction of immunogenic peptides exemplified with HIV V3 sequences.
  • Robbins, JB Schneerson, R Polysaccharide-protein conjugates: A new generation of vaccines. J. Infect. Dis. 1990 161 821–832.
  • Etlinger, HM Gillesden, D Lahm, HW Matile, H Schonfeld, HJ Trzeciak, A Use of prior vaccination for the development of new vaccines. Science 1990 249 423–425.
  • Bersofsky, JA Cease, KB Cornette, JL Spouge, JL Margalit, H Berkower, IJ Good, MF Miller, LH DeLise, C Protein antigenic structures recognised by T-cells: Potential applications to vaccine design. Immunol. Revs. 1987 98 9–52.
  • Rothbard, JB Taylor, WR A sequence pattern common to T-cell epitopes. EMBO J. 1998 7 93–100.
  • Gao, X-M Liew, FY Tite, JP Identification and characterisation of the Th epitopes in the nucleoprotein of influenza A virus. J. Immunol. 1989 143 3007–3014.
  • Falk, K Rotzschke, O Stevanovic, S Jung, G Rammensee, HG Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 1991 351 290–296 Demonstrates the principle of allele specific amino acid sequence motifs in peptides associated with MHC class I in mice.
  • Pamer, EG Harty, JT Bevan, MJ Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 1991 353 852–855.
  • Rotzschke, O Falk, K Stevanovic, S Jung, G Walden, P Rammensee, HG Exact prediction of a natural T-cell epitope. Eur. J. Immunol. 1991 21 2891–2894.
  • Lussow, AR Del Giudice, G Renia, L Mazier, D Verhave, JP Verdinin, AS Pessi, A Louis, JA Lambert, PH Use of tuberculin purified protein derivative Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guerin primed mice overcomes H-2 restriction of the antibody responses and avoids the need for adjuvants. Proc. Natl. Acad. Sci. USA 1990 87 2960–2964.
  • Del Giudice G New carriers and adjuvants in the development of vaccines. Curr. Opin. Immunol. 1992 4 454–459.
  • Lussow, AR Barrios, C van Embden, J Lambert, PH Del Giudice, G Mycobacterial heatshock proteins as carrier molecules. Eur. J. Immunol. 1991 21 2297–2302 Documents the potent carrier effect of mycobacterial heat shock proteins for conjugated peptide entirely substituting for conventional adjuvants.
  • Sinigaglia, F Gutterger, M Kilgus, J Doran, DM Matile, H Etlinger, H Trzeciak, A Gillessen, D Pink, JRL A malarial T-cell epitope recognised in association with most mouse and human MHC class II molecules. Nature 1988 336 778–780 First demonstration of the existence of ‘universal’ T-cell epitopes that bind to a wide range of MHC molecules.
  • Panina-Bordignon, P Tan, A Termitjtelen, A Demotz, S Corradin, G Lanzavecchia, A Universally immunogenic T-cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T-cells. Eur. J. Immunol. 1989 19 2237–2242.
  • Ho, PC Mutch, DA Winkel, KD Saul, AJ Jones, GL Doran, TJ Rzepczyk, CM Identification of two promiscuous T-cell epitopes from Tetanus toxoid. Eur. J. Immunol. 1990 20 477–483.
  • Roche, PA Crosswell, P High-affinity binding of an influenza haemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 1990 144 1849–1856.
  • O'Sullivan, D Arrhenius, T Sidney, J Del Guericio, MF Albertson, M Wall, M Oseroff, C Southwood, S Colon, SM Gaeta, FCA Sette, A On the interactions of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J. Immunol. 1991 147 2663–2669.
  • Mackett, M Vaccinia virus as a vector for delivering foreign antigens. Semin. Virol. 1990 1 39–47.
  • Stover, CK De La Cruz, UF Fuerst, TR Burlein, JE Benson, LA Bennet, LT Bansal, GP Young, JK Lee, MH Hatfull, GF Snapper, SB Barletta, RG Jacobs, WR Jr Bloom, BR New use of BCG for recombinant vaccines. Nature 1991 351 456–460.
  • Dougan, G Tite, J Live bacterial vaccines for delivering foreign antigens. Semin. Virol. 1990 1 29–37.
  • Springer, TA Adhesion receptors of the immune system. Nature 1990 346 425–434.
  • Rhodes, J Evidence for an intercellular covalent reaction essential in antigen specific T-cell activation. J. Immunol. 1989 143 425–434 Describes a novel covalent chemical mechanism in antigen specific T-cell activation that has subsequently provided an unprecedented target for adjuvanting humoral and cell-mediated immune response to vaccine antigens.
  • Gao, X-M Rhodes, J An essential role for constitutive Schiff base forming ligands in antigen presentation to murine T-cell clones. J. Immunol. 1990 144 2883–2890.
  • Rhodes, J Erythrocyte rosettes provide an analogue for Schiff base formation in specific T-cell activation. J. Immunol. 1990 145 463–469.
  • Novogrodsky, A Katchalski, E Induction of lymphocyte transformation by sequential treatment with neuraminidase and galactose oxidase. Proc. Natl. Acad. Sci. USA 1973 70 1824–1827.
  • Novogrodsky, A Induction of lymphocyte cytotoxicity by modification of the effector or target cells with periodate or with neuraminidase and galactose oxidase. J. Immunol. 1975 114 1089–1093.
  • Zheng, B Brett, SJ Tite, JP Lifely, MR Brodie, TA Rhodes, J Galactose oxidation in the design of immunogenic vaccines. Science 1992 256 1560–1563 Describes an entirely new approach in which covalent chemical events essential in immune induction are amplified to produce potent adjuvant effects for a wide range of vaccines without the use of gels, oil-based vehicles, carriers or bacterial extracts.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.